Our results and these possible stabilizing mechanisms further underscored that serum SOX2OT and ANRIL may serve as potential novel biomarkers for diagnosis and prognosis of NSCLC. This evidence concerns the gene CDKN2B-AS1 and non-small cell lung carcinoma.